AbbVie Gets a Hold Rating from Credit Suisse

By Carrie Williams

Credit Suisse analyst Vamil Divan maintained a Hold rating on AbbVie (NYSE: ABBV) yesterday and set a price target of $65. The company’s shares closed yesterday at $67.87, close to its 52-week high of $68.12.

According to TipRanks.com, Divan is a 3-star analyst with an average return of 2.6% and a 51.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Alder Biopharmaceuticals, and Adamas Pharmaceuticals.

AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $74.08.

The company has a one year high of $68.12 and a one year low of $55.06. Currently, AbbVie has an average volume of 5.64M.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABBV in relation to earlier this year. Most recently, in March 2017, Thomas Hurwich, the VP, Controller of ABBV sold 7,258 shares for a total of $450,830.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.